Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in Chemotherapy-Naive Androgen Independent Prostate Cancer
NCT00272038Phase 2Completed
- Sponsor
- Oncology Specialists
- Start
- Dec 2005
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in castration-resistant prostate cancer (CRPC), sponsored by Oncology Specialists. Primary endpoint: Overall Clinical Benefit of Tarceva in CRPC at 5 years. Started Dec 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT00272038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272038.